VTV THERAPEUTICS AND M42’S IROS ANNOUNCE SUBMISSION OF PHASE 2 CLINICAL STUDY PROTOCOL FOR CADISEGLIATIN IN TYPE 2 DIABETES TO THE UNITED ARAB EMIRATES DEPARTMENT OF HEALTH

Reuters · 1d ago

Please log in to view news